Probing the mechanism of reduced in vivo potency of insulin detemir [PDF]
, 2023 Christian L. Brand, Jeppe Sturis
openalex +1 more source
Funktionelle Insulintherapie (FIT) beim Typ-1-Diabetes [PDF]
, 2018 Zusammenfassung: Das Ziel der Insulinbehandlung bei Patienten mit Diabetes mellitus Typ 1 besteht darin, eine nahezu normoglykämische Blutzuckereinstellung unter Vermeidung von schweren Hypoglykämien zu erreichen, um einerseits die Entwicklung von mikro-
Lehmann, R., Pavlicek, V.
core
An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: A randomised controlled trial. [PDF]
, 2017 AIM: To evaluate an additional rapid-acting insulin bolus on postprandial lipaemia, inflammation and pro-coagulation following high-carbohydrate high-fat feeding in people with type 1 diabetes.
Cefalu W. +10 more
core +2 more sources
Indian Journal of Endocrinology and Metabolism, 2013 Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Faisal Hashim +2 more
doaj +1 more source
A Pharmaceutical Innovation – Is it Worth the Money? Whose Money? [PDF]
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the benefit list of social health insurance.
Michele Sennhauser, Peter Zweifel
core
Evidence review : liraglutide for the treatment of type 2 diabetes [PDF]
, 2011 This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National Institute
Cummins, E. (Ewen) +4 more
core
Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
Drug, Healthcare and Patient Safety, 2010 Kitty Poon, Allen B KingDiabetes Care Center, Salinas, CA, USAAbstract: Diabetes mellitus is a growing public health concern in the US and worldwide. Insulin therapy is the cornerstone of diabetes therapy, and the use of basal insulins will increase as ...
Kitty Poon, Allen B King
doaj
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes [PDF]
, 2008 Julio Rosenstock +5 more
openalex +1 more source
Assessment of efficiency of application of various analogues of insulin in treatment of diabetes type 2 [PDF]
Саратовский научно-медицинский журнал, 2014 Purpose: to estimate efficiency of treatment of analogues of insulin Glargin and insulin Detemir in patients with diabetes type 2. Material and methods.
Rodionova T.l., Orlova M.M.
doaj
Indian Journal of Endocrinology and Metabolism, 2013 Background: A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care ...
Hicham Boussouf +2 more
doaj +1 more source